Regen BioPharma Inc. has identified a series of small molecule drugs that inhibit NR2F6. Regen’s screening process demonstrated that its recently identified novel chemical compounds appear to inhibit NR2F6 and show potential for treating autoimmune diseases such as Lupus.  The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) which may be important in developing therapies for treating autoimmune diseases like Lupus. T...